Catalyst Pharmaceuticals (NASDAQ:CPRX) Given New $36.00 Price Target at Truist Financial

Catalyst Pharmaceuticals (NASDAQ:CPRX) had its price objective increased by Truist Financial from $30.00 to $36.00 in a research report released on Monday morning,Benzinga reports. The brokerage currently has a buy rating on the biopharmaceutical company’s stock.

Several other research firms have also recently commented on CPRX. Citigroup lifted their price target on Catalyst Pharmaceuticals from $27.00 to $31.00 and gave the company a “buy” rating in a report on Friday, August 9th. HC Wainwright reaffirmed a “buy” rating and set a $30.00 price target on shares of Catalyst Pharmaceuticals in a research report on Friday, November 8th. Finally, StockNews.com raised shares of Catalyst Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Friday, August 9th. Six equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus target price of $30.50.

Catalyst Pharmaceuticals Stock Down 4.9 %

Shares of Catalyst Pharmaceuticals stock opened at $21.69 on Monday. Catalyst Pharmaceuticals has a fifty-two week low of $13.00 and a fifty-two week high of $24.27. The business’s fifty day moving average is $20.97 and its two-hundred day moving average is $18.28. The firm has a market cap of $2.59 billion, a PE ratio of 18.38, a P/E/G ratio of 3.67 and a beta of 0.75.

Insider Activity at Catalyst Pharmaceuticals

In other Catalyst Pharmaceuticals news, insider Steve Miller sold 150,000 shares of the firm’s stock in a transaction dated Tuesday, August 20th. The stock was sold at an average price of $20.35, for a total value of $3,052,500.00. Following the transaction, the insider now directly owns 675,124 shares of the company’s stock, valued at $13,738,773.40. This trade represents a 18.18 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director David S. Tierney sold 15,000 shares of the company’s stock in a transaction dated Wednesday, August 21st. The stock was sold at an average price of $20.10, for a total value of $301,500.00. Following the completion of the sale, the director now directly owns 348,874 shares of the company’s stock, valued at $7,012,367.40. The trade was a 4.12 % decrease in their position. The disclosure for this sale can be found here. Company insiders own 11.00% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in CPRX. Arizona State Retirement System grew its holdings in Catalyst Pharmaceuticals by 2.2% during the 2nd quarter. Arizona State Retirement System now owns 29,733 shares of the biopharmaceutical company’s stock valued at $461,000 after purchasing an additional 654 shares in the last quarter. GAMMA Investing LLC grew its stake in shares of Catalyst Pharmaceuticals by 62.1% during the third quarter. GAMMA Investing LLC now owns 1,778 shares of the biopharmaceutical company’s stock valued at $35,000 after acquiring an additional 681 shares in the last quarter. Ameritas Investment Partners Inc. increased its position in shares of Catalyst Pharmaceuticals by 6.9% during the first quarter. Ameritas Investment Partners Inc. now owns 11,116 shares of the biopharmaceutical company’s stock worth $177,000 after acquiring an additional 720 shares during the last quarter. XTX Topco Ltd lifted its stake in shares of Catalyst Pharmaceuticals by 7.5% in the second quarter. XTX Topco Ltd now owns 11,134 shares of the biopharmaceutical company’s stock worth $172,000 after acquiring an additional 773 shares in the last quarter. Finally, Strategic Advocates LLC boosted its holdings in Catalyst Pharmaceuticals by 6.5% in the second quarter. Strategic Advocates LLC now owns 14,142 shares of the biopharmaceutical company’s stock valued at $219,000 after purchasing an additional 864 shares during the last quarter. 79.22% of the stock is owned by institutional investors and hedge funds.

Catalyst Pharmaceuticals Company Profile

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.